Skip to content
HOME
ABOUT US
MEMBERSHIP
JOURNAL
USEFUL RESOURCES
EVENTS
CONTACT US
MEMBER’S AREA
HOME
ABOUT US
MEMBERSHIP
JOURNAL
USEFUL RESOURCES
EVENTS
CONTACT US
MEMBER’S AREA
Risks, harms and clinical implications of NPS
Master8
2022-04-27T21:51:51+00:00
Risks and harms of NPS from the user’s perspective and regional differences in prevalence: social research results from Germany
B. Werse (Germany)
Recreational stimulants compared to cannabis: a psychobiological overview
Parrott
(UK)
New Psychoactive Substances: a threat to health security
Evans-Brown (EMCCDA)
Club drugs and induced psychopathology
Martinotti (Italy)
Acute effects of a moderate dose of a synthetic cannabinoid (JWC-018): implications for psychosis
E. L. Theunissen (The Netherlands)
Performance and Imaging Enhancing Drugs and related psychopathology: clinical issues
P. L. Simonato (Italy)
NPS, behaviour and the mind: controlled and naturalistic study with NPS
Ramaekers (The Netherlands)
Did the use of crystal meth increase with the ease of COVID 19 lockdown restrictions, leading to increased hospital admissions?
Manning et al (UK)
Clinical management of NPS in different settings (clinical cases)
Metastasio, O. Bowden-Jones (UK)
Page load link
Go to Top